Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06280482 · ClinicalTrials.gov registry record · Phase 1
Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
A Phase 1 study of Smooth Muscle Dysfunction Syndrome (SMDS), sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06280482 is a Phase 1 study of Smooth Muscle Dysfunction Syndrome (SMDS) that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06280482, a Phase 1 study of Smooth Muscle Dysfunction Syndrome (SMDS), is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.
Conditions Studied
Interventions
- DRUG Nicotinamide riboside (NR)
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2027-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06280482
The ClinicalTrials.gov registry entry for NCT06280482 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smooth Muscle Dysfunction Syndrome (SMDS) appearing as the primary indexed condition, and to 1 intervention - of which Nicotinamide riboside (NR) is the first listed.
NCT06280482 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06280482 about?
NCT06280482 is a clinical study titled "Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)". The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment w...
What is the current status of trial NCT06280482?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-03-06. Estimated completion is 2027-07-25.
What conditions does trial NCT06280482 study?
This clinical trial studies the following conditions: Smooth Muscle Dysfunction Syndrome (SMDS).
What interventions are being tested in trial NCT06280482?
The interventions under investigation include: Nicotinamide riboside (NR) (DRUG).
Who is sponsoring clinical trial NCT06280482?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06280482 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.